Piper Sandler Maintains Overweight on Definium Therapeutics, Lowers Price Target to $48

Benzinga Newsdesk www.benzinga.com Negative 80.7%

Neg 80.7% Neu 0% Pos 0%

Piper Sandler analyst David Amsellem maintains Definium Therapeutics (NASDAQ:DFTX) with a Overweight and lowers the price target from $49 to $48.